After an incredible performance in late March, when shares of Acadia Pharmaceuticals (ACAD 2.56%) jumped up 23%, they have once again exploded today, up 40% intraday. What's behind these massive leaps for this pharmaceutical company, and is there more on the way? In this video, Motley Fool health-care analyst David Williamson tells investors about the drug that has Acadia investors so excited, why it has so many competitive advantages, and what investors need to watch from here.
Acadia Leaps Toward the Finish Line
By Dave Williamson
-
Apr 11, 2013 at 6:22PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NASDAQ: ACAD
Acadia Pharmaceuticals

Market Cap
$3B
Today's Change
(2.56%) $0.42
Current Price
$17.02
Price as of May 17, 2022, 4:21 p.m. ET
Shares of Acadia Pharmaceuticals exploded today. What's behind this stock price skyrocket?
Stocks Mentioned

Acadia Pharmaceuticals
ACAD
$17.02
(2.56%)
$0.42

Pfizer Inc.
PFE
$51.34
(1.31%)
$0.67

Bristol Myers Squibb Company
BMY
$78.08
(1.51%)
$1.17

Eli Lilly and Company
LLY
$300.53
(0.38%)
$1.15
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles

Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday

Why Acadia Pharmaceuticals Stock Is Rocketing Today

Why Acadia Pharmaceuticals Stock Is Crashing Today

What's Behind Acadia Pharmaceuticals' Mixed Q3 Results

2 Biotech Stocks With Major Incoming Catalysts
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.